NewAmsterdam Pharma (NAMS) News Today $23.41 -0.59 (-2.46%) Closing price 04:00 PM EasternExtended Trading$23.42 +0.00 (+0.02%) As of 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period DCF Advisers LLC Grows Position in NewAmsterdam Pharma (NASDAQ:NAMS)DCF Advisers LLC increased its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 162.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 89,400 shares of the company's stock after buying an additional 55,400 shares during thMarch 22 at 6:05 AM | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Trading 3.4% Higher - What's Next?NewAmsterdam Pharma (NASDAQ:NAMS) Trading Up 3.4% - Here's WhyMarch 21, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Sold by US Bancorp DEUS Bancorp DE cut its holdings in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 80.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,804 shares of the company's stock after selling 11,619 shares during the period. US Bancorp DE's holdingsMarch 18, 2025 | marketbeat.comBrokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) Target Price at $43.33March 16, 2025 | americanbankingnews.comNewAmsterdam Pharma Company (NAMS) Gets a Buy from Piper SandlerMarch 12, 2025 | markets.businessinsider.comNewAmsterdam Pharma (NASDAQ:NAMS) Receives Consensus Rating of "Buy" from BrokeragesNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) has been assigned a consensus recommendation of "Buy" from the six ratings firms that are currently covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating. The average 1 year price target among anMarch 11, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Director James N. Topper Purchases 4,005 SharesNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) Director James N. Topper bought 4,005 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The shares were purchased at an average cost of $21.02 per share, for a total transaction of $84,185.10. Following the acquisition, the director now owns 3,012,434 shares of the company's stock, valued at $63,321,362.68. This represents a 0.13 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.March 7, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Sees Large Volume Increase - Time to Buy?NewAmsterdam Pharma (NASDAQ:NAMS) Sees Strong Trading Volume - Should You Buy?March 7, 2025 | marketbeat.comInsider Buying: NewAmsterdam Pharma (NASDAQ:NAMS) Director Buys 4,005 Shares of StockMarch 7, 2025 | insidertrades.comDirector’s Bold Move: Major Stock Purchase in NewAmsterdam Pharma!March 6, 2025 | tipranks.comNewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells $3,055,500.00 in StockNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) CAO Louise Frederika Kooij sold 150,000 shares of the stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total value of $3,055,500.00. Following the transaction, the chief accounting officer now owns 15,000 shares of the company's stock, valued at approximately $305,550. The trade was a 90.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.March 6, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Up 3.9% - Should You Buy?NewAmsterdam Pharma (NASDAQ:NAMS) Trading 3.9% Higher - What's Next?March 5, 2025 | marketbeat.comNewAmsterdam Pharma price target raised to $41 from $35 at GuggenheimMarch 3, 2025 | markets.businessinsider.comLeerink Partnrs Has Negative Outlook of NAMS FY2028 EarningsNewAmsterdam Pharma (NASDAQ:NAMS - Free Report) - Equities researchers at Leerink Partnrs decreased their FY2028 EPS estimates for shares of NewAmsterdam Pharma in a research report issued to clients and investors on Thursday, February 27th. Leerink Partnrs analyst R. Ruiz now anticipates that thMarch 3, 2025 | marketbeat.comWilliam Blair Has Negative Forecast for NAMS Q1 EarningsNewAmsterdam Pharma (NASDAQ:NAMS - Free Report) - Investment analysts at William Blair reduced their Q1 2025 earnings estimates for shares of NewAmsterdam Pharma in a note issued to investors on Wednesday, February 26th. William Blair analyst M. Phipps now forecasts that the company will earn ($0March 3, 2025 | marketbeat.comNewAmsterdam Pharma files for $500M mixed securities shelfMarch 1, 2025 | seekingalpha.comNewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of ObicetrapibMarch 1, 2025 | seekingalpha.comNewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of ObicetrapibMarch 1, 2025 | seekingalpha.comNewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Yearly Results: Here's What Analysts Are Forecasting For This YearFebruary 28, 2025 | finance.yahoo.comNewAmsterdam Pharma files $500M mixed securities shelfFebruary 28, 2025 | markets.businessinsider.comScotiabank Issues Positive Forecast for NewAmsterdam Pharma (NASDAQ:NAMS) Stock PriceScotiabank increased their price objective on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Thursday.February 28, 2025 | marketbeat.comNewAmsterdam Pharma: A Mispriced Bet On A Cholesterol RevolutionFebruary 28, 2025 | seekingalpha.comNeedham & Company LLC Cuts NewAmsterdam Pharma (NASDAQ:NAMS) Price Target to $42.00Needham & Company LLC reduced their target price on shares of NewAmsterdam Pharma from $46.00 to $42.00 and set a "buy" rating on the stock in a research note on Thursday.February 28, 2025 | marketbeat.comNewAmsterdam Pharma’s 2024 Financial Results and Clinical ProgressFebruary 28, 2025 | tipranks.comNewAmsterdam Pharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS LagsFebruary 27, 2025 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: NewAmsterdam Pharma Company (NAMS) and Organogenesis Holdings (ORGO)February 27, 2025 | markets.businessinsider.comNewAmsterdam Pharma (NASDAQ:NAMS) Issues Earnings Results, Misses Estimates By $0.47 EPSNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.95) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.47).February 27, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Trading 8.9% Higher - Here's What HappenedNewAmsterdam Pharma (NASDAQ:NAMS) Trading Up 8.9% - Here's WhyFebruary 27, 2025 | marketbeat.comNewAmsterdam Pharma Company (NAMS) Receives a Buy from William BlairFebruary 26, 2025 | markets.businessinsider.comPromising Drug Developments and Positive Trial Results Drive Buy Rating for NewAmsterdam PharmaFebruary 26, 2025 | tipranks.comNewAmsterdam Pharma Co NV (NAMS) Reports 2024 Financial Results and Provides Corporate UpdateFebruary 26, 2025 | gurufocus.comNewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate UpdateFebruary 26, 2025 | globenewswire.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Up - What's Next?NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Up - Here's WhyFebruary 25, 2025 | marketbeat.comNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in MarchFebruary 25, 2025 | globenewswire.comNewAmsterdam Pharma Company N.V. (NAMS): Among the Oversold Biotech Stocks to Buy NowFebruary 24, 2025 | insidermonkey.comHandelsbanken Fonder AB Invests $4.82 Million in NewAmsterdam Pharma (NASDAQ:NAMS)Handelsbanken Fonder AB bought a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 187,404 shares of the company's stock, valued at apprFebruary 24, 2025 | marketbeat.comTimesSquare Capital Management LLC Buys 640,329 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)TimesSquare Capital Management LLC increased its stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 250.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 895,574 shares of the company's stockFebruary 20, 2025 | marketbeat.comNewAmsterdam Pharma (NAMS) Projected to Post Quarterly Earnings on WednesdayNewAmsterdam Pharma (NASDAQ:NAMS) will be releasing earnings before the market opens on Wednesday, February 26.February 19, 2025 | marketbeat.comRA CAPITAL MANAGEMENT, L.P. Expands Stake in NewAmsterdam Pharma Co NVFebruary 15, 2025 | gurufocus.comAndreas Halvorsen Reduces Stake in NewAmsterdam Pharma Co NVFebruary 15, 2025 | gurufocus.comNewAmsterdam Pharma (NASDAQ:NAMS) Given Consensus Rating of "Buy" by BrokeragesNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) has earned a consensus recommendation of "Buy" from the six analysts that are covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that haFebruary 14, 2025 | marketbeat.comabrdn plc Increases Stake in NewAmsterdam Pharma (NASDAQ:NAMS)abrdn plc grew its stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 38.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 179,060 shares of the company's stock after purchasing an additional 50,000 shares during thFebruary 10, 2025 | marketbeat.comNewAmsterdam Pharma Co NV (NAMS) Announces Inducement Share Options for New HiresFebruary 7, 2025 | gurufocus.comNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 7, 2025 | globenewswire.comJennison Associates LLC Raises Holdings in NewAmsterdam Pharma (NASDAQ:NAMS)Jennison Associates LLC increased its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 291.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,998,541 shares of the company's stock afFebruary 4, 2025 | marketbeat.comChina Universal Asset Management Co. Ltd. Buys New Position in NewAmsterdam Pharma (NASDAQ:NAMS)China Universal Asset Management Co. Ltd. purchased a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 19,589 sharFebruary 3, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Trading Up 4.1% - Time to Buy?NewAmsterdam Pharma (NASDAQ:NAMS) Trading 4.1% Higher - Still a Buy?January 31, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Bought by JPMorgan Chase & Co.JPMorgan Chase & Co. raised its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 176.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 22,351 shares of the company's stock after buyJanuary 30, 2025 | marketbeat.comNewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech ConferenceJanuary 29, 2025 | markets.businessinsider.comNewamsterdam pharma CFO sells shares worth $1.5 millionJanuary 29, 2025 | msn.com Remove Ads Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address NAMS Media Mentions By Week NAMS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NAMS News Sentiment▼1.100.68▲Average Medical News Sentiment NAMS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NAMS Articles This Week▼34▲NAMS Articles Average Week Remove Ads Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ascendis Pharma A/S News Sarepta Therapeutics News Vaxcyte News Qiagen News Roivant Sciences News Revolution Medicines News Lantheus News Legend Biotech News TG Therapeutics News BridgeBio Pharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NAMS) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NAMS Stock Free NAMS Stock Alerts